All
  • All
  • Insight
  • Research Services
  • Preclinical CRO
  • Animal Resource Bank
CN
中文 English

Efficacy Evaluation

We strictly adhere to national regulations on laboratory animal welfare and ethics, establishing a comprehensive system for microbial quality control and genetic background verification throughout the entire process. This ensures that every experimental mouse strain we release is genetically pure, healthy, and free of specific pathogens, providing a highly reproducible foundation for your research.

Explore more

Efficacy Evaluation

Related Resources

CDX mouse subcutaneous tumor model

Promotional price tumor model 620 yuan ， Including drug administration and data monitoring, *Includes   Nude mice or conventional mice   , does not include immune deficiency Trapped rat  。

* All cell lines participating in the study are guaranteed to establish tumors.   , and all have been verified; image source: Aniphe BioLab

 

A549—human non-small cell lung cancer cell line

 

1. Cell background: A549 A cell line is 1972 Year of GiardDJ Established through the transplantation and culture of lung cancer tissue, derived from a single individual. 58 A white male of [age] years old

2. Cell morphology: Epithelial-like, adherent growth

3. Culture conditions: 90%F12K ， 10% FBS ， 1% P/S ， 37°C 、 5% CO2

4. Passage cycle: 2-3 Heaven

5. Recipient mouse ： Balb/c-nude

6. Vaccination dose ： 1x10^7/100 μL 、 5x10^6/100 μL

7. Tumor formation time: 2 About a week

 

HepG2—human hepatocellular carcinoma cell line

 

1. Cell background: Derived from a 15 A white male patient, years old, with hepatocellular carcinoma.

2. Cell morphology: Epithelial cell-like

3. Culture conditions: 90% DMEM + 10% FBS or 90%1640+10%FBS ， 37°C ， 5% CO2 , incubator humidity 70%-80%

4. Passage cycle: 3-4 Heaven

5. Recipient mouse: Balb/c-nude 6. Vaccination dose: 2x10^6/200 μL (References), 1x107/100μL 7. Tumor formation time: 2 About a week

 

Hep3B—human hepatocellular carcinoma cell line

 

 

 

1. Cell background: Founded in 1979 Year, originating from a person suffering from liver cancer 7 A black boy of age

2. Cell morphology: Epithelial cell-like

3. Culture conditions: MEM+10%FBS + 1% P/S + NEAA

4. Passage cycle: 3-4 Heaven

5. Recipient mouse: Balb/c-nude 6. Vaccination dose: 1x107/100μL 7. Tumor formation time: 3 About a week

 

HeLa—human cervical cancer cell line

 

 

1. Cell background: Hela The cell line is the first derived from human tissue and maintained in continuous culture, preserving aneuploid epithelial‑like characteristics. Hela Cells are composed of G·D·Gey Waiting in 1951 Year from 31 Establishment of cervical cancer in Black women

2. Cell morphology: Oval or spindle-shaped, growing attached to the substrate.

3. Culture conditions: 90% DMEM，10% Fetal bovine serum, 100U/ml Dual antibody, 37°C 、 5% CO2

4. Passage cycle: 2-3 Heaven

5. Recipient mouse ： Balb/c-nude

6. Vaccination dose: 1x10^7/100 μL

7. Tumor formation time: 2-3 About a week

 

HT-29 human colorectal cancer cell line

 

1. Cell background: It is in 1964 Year of Fog and Tempering Two scientists isolated and discovered that it originated from a patient with colorectal cancer. (CRC) of 44 Primary tumors in white women of a certain age

2. Cell morphology: Epithelial cells tend to grow in clusters and, when in good condition, exhibit an irregular triangular morphology.

3. Culture conditions ： 90%1640+10%FBS ， 37°C ， 5% CO2

4. Passage cycle: 3-4 Heaven

5. Recipient mouse: Balb/c-nude

6. Vaccination dose: 5x10^6/100 μL 、 1x10^7/100 μL

7. Tumor formation time: 2 About a week

 

HCT-116 human colorectal cancer cell line

 

1. Cell background: It is in 1979 In year , it was isolated and established by the researchers at the time from a male patient with colon cancer. 3 One of the malignant cells of the tumor

2. Cell morphology: Epithelial cell-like , Polygonal, growing adherent to the substrate

3. Culture conditions: 90% DMEM + 10% FBS ， 37°C ， 5% CO2 4. Passage cycle: 2-3 Heaven

5. Recipient mouse: Balb/c-nude 6. Vaccination dose: 1x107/100μL 7. Tumor formation time: 2-3 About a week

 

SW620—Human Colon Cancer Cell Line

 

1. Cell background: Human colon cancer cells SW620 A cell originates from a single 51 It was isolated from a male Caucasian population, by A.Leibovitz Wait until a colony is established from a lymph node.

2. Cell morphology : Epithelial-like

3. Culture conditions ： 90%1640+10% FBS+1%PS

4. Passage cycle ： 1-2 Heaven

5. Recipient mouse: Balb/c-nude

6. Vaccination dose: 1x10^7/100 μL

7. Tumor formation time: 2-3 About a week

 

SK-BR-3 human breast cancer cell line

 

1. Cell background: is 1970 Year from a 43 The blood type of the year is A+ It was isolated from pleural effusion cells of a Caucasian female patient with adenocarcinoma, who had previously received radiotherapy, corticosteroids, and cyclophosphamide, and… 5- Fluorouracil therapy

2. Cell morphology: Epithelial cell-like

3. Culture conditions: 90%1640+10% FBS+1% P/S ， 37°C ， 5% CO2

4. Passage cycle: 2-3 Heaven

5. Recipient mouse: Balb/c-nude

6. Vaccination dose: 1x10^7/100 μL

7. Tumor formation time: 2-3 About a week

 

MDA-MB-231- Human breast cancer cell line

 

1. Cell background: From patients with metastatic breast adenocarcinoma 51 Pleural effusion in female patients is frequently employed in studies on the pathogenesis and clinical applications of breast diseases.

2. Cell morphology: Epithelial-like, adherent growth

3. Culture conditions: 90%DMEM，10% Fetal bovine serum (premium grade), 100U/ml Dual antibody, 37°C 、 5% CO2

4. Passage cycle: 2-3 Heaven

5. Recipient mouse: Balb/c nude

6. Vaccination dose: 1x10^7/100 μL

7. Tumor formation time: 3 About a week

 

PC-3 human prostate cancer cell line

 

 

1. Cell background: PC-3 The cell originated from a 62 White male of age IV Bone metastases in patients with prostate adenocarcinoma of stage

2. Cell morphology: Epithelial-like, adherent growth

3. Culture conditions: 90% 1640 ，10% Fetal bovine serum (high quality), 100U/ml Dual antibody, 37°C 、 5% CO2

4. Passage cycle: 2-3 Heaven

5. Recipient mouse: Balb/c nude

6. Vaccination dose: 1x10^7/100 μL

7. Tumor formation time: 3 About a week

 

Hepa1-6 mouse hepatocellular carcinoma cell line

 

 

1. Cell background: Hepa1-6 Cells are C57/L Produced in mice BW7756 A derivative strain of mouse hepatocellular carcinoma cells

2. Cell morphology: Epithelial-like, adherent growth

3. Culture conditions: 88%DMEM (including LNaHCO3 1.5g/L) ，10% High-quality fetal bovine serum, 100U/ml Dual antibody, 1% Sodium pyruvate, 37°C 、 5% CO2

4. Passage cycle: 2-3 Heaven

5. Recipient mouse: C57BL/6

6. Vaccination dose: 1x10^7/100 μL

7. Tumor formation time: 2-3 About a week

 

CT26–mouse colon cancer cell line

 

1. Cell background: CT26 Cells are N- Nitroso -N- Methyl carbamate (NNMU) An undifferentiated colon cancer cell line induced to form, with the clonally derived subline named CT26.WT

2. Cell morphology: Fibroblast-like

3. Culture conditions: 90%1640+10% FBS+1% P/S ， 37°C ， 5% CO2

4. Passage cycle: 1-2 Heaven   

5. Recipient mouse:   BALB/c

6. Vaccination dose: 5x10^5/100 μL 、 1x10^6/100 μL

7. Tumor formation time: 10 About a day

 

MC38—mouse colon cancer cell line

 

1. Cell background: MC38 Cells are derived from C57BL/6 A mouse colon adenocarcinoma cell line that grows adherently and exhibits a fibroblast-like morphology.

2. Cell morphology: Epithelial-like, adherent growth

3. Culture conditions: 90% RPMI-1640 ，10% Fetal bovine serum, 100U/ml Dual antibody, 37°C 、 5% CO2

4. Passage cycle: 2-3 Heaven

5. Recipient mouse: C57BL/6

6. Vaccination dose: 5x10^5/100 μL 、 1x10^6/100 μL

7. Tumor formation time: 7-10 About a day

 

B16F10—mouse skin melanoma cell line

 

 

1. Cell background: B16-F10 A cell is B16-F0 Cell subline

2. Cell morphology: Epithelial cell-like

3. Culture conditions: DMEM/F12+10%FBS+1%P/S ， 37°C ， 5% CO2

4. Passage cycle: 2-3 Heaven

5. Recipient mouse: C57BL/6

6. Vaccination dose: 5x10^5/100 μL 、 1x10^6/100 μL

7. Tumor formation time: 10 About a day

 

4T1 mouse mammary carcinoma cell line

 

1. Cell background: 4T1 is from 410.4 Unmutagenized and unselected in the tumor strain 6- Thioguanine-resistant cell line

2. Cell morphology: Epithelial-like, adherent growth

3. Culture conditions: 90%1640+10% FBS+1%PS

4. Passage cycle: 1-2 Heaven

5. Recipient mouse: BALB/c

6. Vaccination dose: 5x10^5/100 μL 、 1x10^6/100 μL

7. Tumor formation time: 7-10 About a day

 

LA795—Mouse Lung Adenocarcinoma Cell Line

 

1. Cell background: LA795 Cells are in 1979 year 5 It is based on the lunar calendar, derived from T739 Spontaneous papillary lung adenocarcinoma in inbred mice

2. Cell morphology : Epithelioid, adherent growth

3. Culture conditions: 90% DMEM，10% Fetal bovine serum, 100U/ml Dual antibody, 37°C 、 5% CO2

4. Passage cycle: 3-4 Heaven

5. Recipient mouse: C57BL/6

6. Vaccination dose: 1x10^7/100 μL

7. Tumor formation time: 2-3 About a week

 

LLC—mouse lung cancer cell line

 

1. Cell background: LLC The cell is a mouse. Lewis Lung cancer cells, which originate from C57BL Cell lines established from mouse lungs

2. Cell morphology: Epithelial-like, adherent growth

3. Culture conditions ： 90% RPMI-1640 ，10% Fetal bovine serum (high quality), 100U/ml Dual antibody, 37°C 、 5% CO2

4. Passage cycle: 2-3 Heaven

5. Recipient mouse: C57BL/6

6. Vaccination dose: 5x10^5/100 μL 、 1x10^6/100 μL

7. Tumor formation time: 10 About a day  

 

MFC—mouse gastric cancer cell line

 

1. Cell background: MFC The cell was discovered by Qian Shusen, Gao Jin, and others. 1985 Established in the year; utilizing sources originating from 615 Mouse forestomach squamous cell carcinoma xenograft FC Tumor tissue, obtained by small‑piece culture, has been passaged. 132 substitute; MFC Cells in 615 Subcutaneous transplantation in mice 100% Success

2. Cell morphology: Epithelial cell-like

3. Culture conditions: 1640 + 10% FBS + 1% P/S ， 37°C ， 5% CO2

4. Passage cycle: 2-3 Heaven

5. Recipient mouse: 615

6. Vaccination dose: 1×10^7 / 100 μL

7. Tumor formation time: 1 About a week

 

If you are interested in our products or services, please contact us via the following channels: experimental animal order email: order@aniphebio.com; research service inquiry email: info@aniphebio.com; consultation phone: 025-8520 8061 (8:30–17:30).